Absence of controlled human data: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did.
A follow-up question about absence of controlled human data that I did not know to ask the first time.
The earlier thread answered what I asked. What I should have asked is below, and I think it is the one that matters.
Building on the opening post rather than restating it.
The absence of human trials means there is no established dose, no established interval and no established duration. Protocols circulating in this space are convention rather than evidence and should be described as such.
Where I would look next, rather than where I would stop.
Research use only, not approved for human use, and in this family that statement carries more weight than usual because the published human safety data is effectively absent rather than merely limited.
The conclusion is tentative; the arithmetic underneath it is not.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
The opening post put the caveat in the right place and I want to underline it.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
That is all I can say without guessing.
Second this, and I would have said it less carefully.
The arithmetic in post #5 is right; the assumption feeding it is the part to check.
Two questions I would want answered before drawing anything from the absence of controlled human data data above: how were the cases selected, and what happened to the ones that dropped out.
The reason absence of controlled human data is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
This is the sort of exchange that makes the archive worth searching.
Answering the question post #12 raises rather than the one it answers.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
Building on post #14 rather than restating it.
Stability in solution is the practical constraint. Dry, these keep well; reconstituted, the supplier's own data usually covers a shorter period than people assume.
Post #12 put the caveat in the right place and I want to underline it.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
My understanding of absence of controlled human data is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
That is what the documentation says. What happens in practice is usually close.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
That is the version I use. It may not be the version that is correct.
I had written a reply contradicting post #16 and deleted it. Here is what survived.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
I am not the right person to answer the follow-up to this.
I read post #17 twice before replying, because I had assumed the opposite.
I have three months of notes on absence of controlled human data and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
A modest claim, modestly supported.
Saving this. It is the version I will quote when the question comes round again.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
If you are new and reading this thread for the answer to absence of controlled human data: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Where the absence of controlled human data discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Taking post #25 at face value and following it one step further.
Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.
On reflection I would soften that slightly.
Answering the question post #25 raises rather than the one it answers.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.